Sub Banner Image

AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial

Market Impact

Vandana Singh

·

July 14, 2025

·

Benzinga

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile.

read more

More from

Benzinga

More

Market Impact

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.